Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis

被引：0
|
作者：
Kenan Aksu
Ayhan Donmez
Yesim Ertan
Gokhan Keser
Vedat Inal
Gonca Oder
Murat Tombuloglu
Yasemin Kabasakal
Eker Doganavsargil
机构：
[1] Ege University School of Medicine Hospital,Internal Medicine
[2] Ege University School of Medicine Hospital,Rheumatology Division
[3] Ege University School of Medicine Hospital,Internal Medicine
来源：
Rheumatology International | 2007年 / 28卷
关键词：
Hodgkin’s lymphoma; Etanercept; Ankylosing spondylitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
It has been well known that anti-TNF drugs might increase lymphoma risk in rheumatoid arthritis (RA), where the rate of lymphoma has already been increased. However, unlike RA, an increased rate of lymphoma has not been reported in ankylosing spondylitis (AS). Hereby, we present a case with AS developing Hodgkin’s lymphoma (HL) following 6 months of etanercept treatment. Pathological analysis revealed mixed cellular type of HL. Although we report a single case, it should be kept in mind that anti-TNF drugs might cause lymphoma development not only in RA, but also in AS.
引用
收藏
相关论文
共 50 条
  • [1] Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis
    Aksu, Kenan
    Donmez, Ayhan
    Ertan, Yesim
    Keser, Gokhan
    Inal, Vedat
    Oder, Gonca
    Tombuloglu, Murat
    Kabasakal, Yasemin
    Doganavsargil, Eker
    RHEUMATOLOGY INTERNATIONAL, 2007, 28 (02) : 185 - 187
  • [2] Non-Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis
    Kenan Aksu
    Seckin Cagirgan
    Nazan Ozsan
    Gokhan Keser
    Fahri Sahin
    Rheumatology International, 2011, 31 : 1645 - 1647
  • [3] Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis
    Aksu, Kenan
    Cagirgan, Seckin
    Ozsan, Nazan
    Keser, Gokhan
    Sahin, Fahri
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (12) : 1645 - 1647
  • [4] Ankylosing spondylitis accompanying with Hodgkin's lymphoma
    Kim, Yun S.
    Kim, Hyun-Sook
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2012, 15 (04) : e68 - e70
  • [5] Multiple sclerosis following etanercept treatment for ankylosing spondylitis
    Pfueller, C. F.
    Seipelt, E.
    Zipp, F.
    Paul, F.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 (05) : 397 - U3
  • [6] Treatment of ankylosing spondylitis: focus on etanercept
    Frech, Tracy
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (01): : 45 - 51
  • [7] Etanercept - In ankylosing spondylitis
    McCormack, PL
    Wellington, K
    BIODRUGS, 2004, 18 (03) : 199 - 205
  • [8] Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
    Dijkmans, Ben
    Emery, Paul
    Hakala, Markku
    Leirisalo-Repo, Marjatta
    Martin Mola, Emilio
    Paolozzi, Laurence
    Salvarani, Carlo
    Sanmarti, Raimon
    Sibilia, Jean
    Sieper, Joachim
    Van den Bosch, Filip
    van der Heijde, Desiree
    van der Linden, Sjef
    Wajdula, Joseph
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (06) : 1256 - 1264
  • [9] Primary synovial non-Hodgkin's lymphoma in association with ankylosing spondylitis
    Khan, SY
    Hutchinson, DG
    RHEUMATOLOGY, 2004, 43 (03) : 391 - 391
  • [10] The economic impact of etanercept and infliximab treatment in ankylosing spondylitis
    Duff, SB
    Yeh, Y
    Yu, EB
    Woolley, JM
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 400 - 400
12345